SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL RECOMMENDATIONS. PART 2
Ekaterina I. Alexeeva,
Tatiana M. Dvoryakovskaya,
Irina P. Nikishina,
Rina V. Denisova,
Nadezhda S. Podchernyaeva,
Ol’ga A. Sukhorukikh,
Lyubov’ S. Shubina,
Vyacheslav G. Chasnyk,
Mikhail M. Kostik https://doi.org/10.15690/vsp.v17i2.1877
Abstract
The article presents modern ideas about the treatment of systemic lupus erythematosus (SLE). The details of the management of patients with SLE during immunosuppressive and genetically engineered therapy is given. The article also reflects the aspects of rehabilitation, prevention of exacerbations, and follow-up care of children with SLE. The criteria for assessing the quality of medical care for children with SLE are presented. The detailed information on systemic lupus erythematosus for patients with SLE and their parents is outlined specifically.
About the Authors
Ekaterina I. Alexeeva
National Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Disclosure of interest: Not declared
Russian Federation
Moscow
Disclosure of interest: Not declared
Tatiana M. Dvoryakovskaya
National Medical Research Center of Children’s Health; Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Disclosure of interest: Not declared
Russian Federation
Moscow
Disclosure of interest: Not declared
Irina P. Nikishina
Nasonova Research Institute of Rheumatology
Russian Federation
Disclosure of interest: Not declared
Russian Federation
Moscow
Disclosure of interest: Not declared
Rina V. Denisova
National Medical Research Center of Children’s Health
Russian Federation
Disclosure of interest: Not declared
Russian Federation
Moscow
Disclosure of interest: Not declared
Nadezhda S. Podchernyaeva
Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Disclosure of interest: Not declared
Russian Federation
Moscow
Disclosure of interest: Not declared
Ol’ga A. Sukhorukikh
Center for Healthcare Quality Assessment and Control
Russian Federation
Disclosure of interest: Not declared
Russian Federation
Moscow
Disclosure of interest: Not declared
Lyubov’ S. Shubina
Center for Healthcare Quality Assessment and Control
Russian Federation
Disclosure of interest: Not declared
Russian Federation
Moscow
Disclosure of interest: Not declared
Vyacheslav G. Chasnyk
St. Petersburg State Pediatric Medical University
Russian Federation
Disclosure of interest: Not declared
Russian Federation
Disclosure of interest: Not declared
Mikhail M. Kostik
St. Petersburg State Pediatric Medical University
Russian Federation
Disclosure of interest: Not declared
Russian Federation
Disclosure of interest: Not declared
References
1. Sakamoto AP, Silva CA, Ferriani MPL, et al. Characterization of chronic arthritis in a multicenter study of 852 childhood-onset systemic lupus erythematosus patients. Rheumatol Int. 2016;36(12):1641–1648. doi: 10.1007/s00296-016-3564-6.
2. Tsai YG, Lee CY, Lin TY, Lin CY. CD8 + Treg cells associated with decreasing disease activity after intravenous methylprednisolone pulse therapy in lupus nephritis with heavy proteinuria. PLoS One. 2014;9(1):e81344. doi: 10.1371/journal.pone.0081344.
3. Sundel R, Solomons N, Lisk L, Study ALM. Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus. 2012;21(13):1433–1443. doi: 10.1177/0961203312458466.
4. Pereira T, Abitbol CL, Seeherunvong W, et al. Three decades of progress in treating childhood-onset lupus nephritis. Clin J Am Soc Nephrol. 2011;6(9):2192–2199. doi: 10.2215/Cjn.00910111.
5. Hui-Yuen JS, Tran T, Taylor J, et al. Use of glucuronidated mycophenolic acid levels for therapeutic monitoring in pediatric lupus nephritis patients. J Clin Rheumatol. 2016;22(2):75–79. doi: 10.1097/Rhu.0000000000000357.
6. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. 2005;52(10):3168–3174. doi: 10.1002/art.21351.
7. Alexeeva EI, Denisova RV, Valieva SI, et al. Efficacy and safety of rituximab in children with systemic lupus erythematosus: results of a retrospective study of the case series. Current pediatrics. 2016;15(5):497–504. (In Russ) doi: 10.15690/vsp.v15i5.1624.
8. Hepburn AL, Narat S, Mason JC. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology. 2010;49(12):2243–2254. doi: 10.1093/rheumatology/keq269.
9. Denisova RV, Alexeeva EI. Anti-CD20 monoclonal antibodies in treatment of haemolytic anemia in a teenage girl with systemic lupus erythematosus. Current pediatrics. 2012;11(6):147–152. (In Russ) doi: 10.15690/vsp.v11i6.508.
10. Alexeeva EI, Denisova RV, Valieva SI, et al. Rituximab in pediatric rheumatology. Current pediatrics. 2010;9(3):54–62. (In Russ).
11. Podchernyaeva NS, Solntseva OA, Soboleva MK, Shcherbakova MYu. Exanthematous lupus erythematosus. Pediatric pharmacology. 2006;3(6):21–28. (In Russ).
12. Romanenko NA, Bessmel’tsev SS, Chechetkin AV. Сorrection of patients’ immune status with human intravenous immunoglobulin. Kazan Med Zh. 2017;98(5):775–783. (In Russ) doi: 10.17750/KMJ2017-775.
13. Maertens J, Cesaro S, Maschmeyer G, et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients. J Antimicrob Chemother. 2016;71(9):2397–2404. doi: 10.1093/jac/dkw157.
14. deVeber G, Chan A, Monagle P, et al. Anticoagulation therapy in pediatric patients with sinovenous thrombosis — a cohort study. Arch Neurol. 1998;55(12):1533–1537. doi: 10.1001/archneur.55.12.1533.
15. Douketis JD, Crowther MA, Julian JA, et al. The effects of low-intensity warfarin on coagulation activation in patients with antiphospholipid antibodies and systemic lupus erythematosus. Thromb Haemost. 1999;82(3):1028–1032.
16. Klyukvina NG, Nasonov EL. Farmakoterapiya sistemnoi krasnoi volchanki: sovremennye reko mendatsii. Russkii meditsinskii zhurnal. 2010;(18):1108. (In Russ).
17. Klyukvina NG. Sovremennaya patogeneticheskaya terapiya sistemnoi krasnoi volchanki. Effektivnaya farmakoterapiya. 2011;(37):74–78. (In Russ).
18. Klyukvina NG. Algorithm for the treatment of systemic lupus erythematosus. Current state of the problem. Meditsinskii sovet. 2016;(8):99–105. (In Russ).
19. Valieva SI, Alexeeva EI, Aleksandrov AE, Dobrovol’skii AE. Use of mycophenolate mophetyl in patient with systemic lupus erythematosus. Current pediatrics. 2006;5(3):88–92. (In Russ).
20. Caltik A, Demircin G, Bulbul M, et al. An unusual case of ANA negative systemic lupus erythematosus presented with vasculitis, long-standing serositis and full-house nephropathy. Rheumatol Int. 2013;33(1):219–222. doi: 10.1007/s00296-010-1540-0.
21. Demircin G, Oner A, Erdogan O, et al. Long-term efficacy and safety of quadruple therapy in childhood diffuse proliferative lupus nephritis. Ren Fail. 2008;30(6):603–609. doi: 10.1080/08860220802132171.
22. Warady BD, Lindsley CB, Robinson RG, Lukert BP. Effects of nutritional supplementation on bone-mineral status of children with rheumatic diseases receiving corticosteroid-therapy. J Rheumatol. 1994;21(3):530–535.
Review
For citations:
Alexeeva E.I., Dvoryakovskaya T.M., Nikishina I.P., Denisova R.V., Podchernyaeva N.S., Sukhorukikh O.A., Shubina L.S., Chasnyk V.G., Kostik M.M. SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL RECOMMENDATIONS. PART 2. Current Pediatrics. 2018;17(2):110-125. (In Russ.) https://doi.org/10.15690/vsp.v17i2.1877
Views:
9227
Email this article 
